ProQR Therapeutics N.V. (PRQR) Reaches $3.10 After 4.00% Down Move; Mackenzie Financial Has Trimmed Its Canadian Nat Res LTD (CNQ) Position

January 14, 2018 - By Ellis Scott

The stock of ProQR Therapeutics N.V. (NASDAQ:PRQR) is a huge mover today! The stock decreased 6.06% or $0.2 during the last trading session, reaching $3.1. About 125,044 shares traded or 9.28% up from the average. ProQR Therapeutics N.V. (NASDAQ:PRQR) has risen 37.60% since January 14, 2017 and is uptrending. It has outperformed by 20.90% the S&P500.The move comes after 6 months negative chart setup for the $98.77M company. It was reported on Jan, 14 by Barchart.com. We have $2.98 PT which if reached, will make NASDAQ:PRQR worth $3.95 million less.

Mackenzie Financial Corp decreased Canadian Nat Res Ltd (CNQ) stake by 11.3% reported in 2017Q3 SEC filing. Mackenzie Financial Corp sold 808,454 shares as Canadian Nat Res Ltd (CNQ)’s stock rose 3.36%. The Mackenzie Financial Corp holds 6.34M shares with $212.42M value, down from 7.15M last quarter. Canadian Nat Res Ltd now has $45.84 billion valuation. The stock increased 1.12% or $0.41 during the last trading session, reaching $37.14. About 1.78 million shares traded. Canadian Natural Resources Limited (NYSE:CNQ) has risen 10.32% since January 14, 2017 and is uptrending. It has underperformed by 6.38% the S&P500.

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA therapeutics for the treatment of genetic disorders. The company has market cap of $98.77 million. The Company’s lead product candidate includes QR-010, a RNA oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; and QR-313, a single-stranded oligonucleotide used for the treatment of epidermolysis bullosa. It currently has negative earnings.

Analysts await ProQR Therapeutics N.V. (NASDAQ:PRQR) to report earnings on February, 27. They expect $-0.49 EPS, down 19.51% or $0.08 from last year’s $-0.41 per share. After $-0.49 actual EPS reported by ProQR Therapeutics N.V. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Among 5 analysts covering ProQR Therapeutics N.V. (NASDAQ:PRQR), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. ProQR Therapeutics N.V. had 6 analyst reports since March 15, 2016 according to SRatingsIntel. JMP Securities maintained it with “Market Outperform” rating and $14 target in Tuesday, March 15 report. The firm earned “Neutral” rating on Monday, June 20 by Chardan Capital Markets. H.C. Wainwright maintained ProQR Therapeutics N.V. (NASDAQ:PRQR) on Tuesday, June 20 with “Buy” rating. As per Thursday, September 29, the company rating was initiated by Janney Capital. The stock of ProQR Therapeutics N.V. (NASDAQ:PRQR) earned “Outperform” rating by Leerink Swann on Tuesday, September 26.

Among 14 analysts covering Canadian Natural Resources Limited (NYSE:CNQ), 11 have Buy rating, 0 Sell and 3 Hold. Therefore 79% are positive. Canadian Natural Resources Limited had 29 analyst reports since July 21, 2015 according to SRatingsIntel. On Friday, April 1 the stock rating was downgraded by TD Securities to “Hold”. Citigroup downgraded Canadian Natural Resources Limited (NYSE:CNQ) on Friday, July 21 to “Neutral” rating. The stock has “Sector Outperform” rating by Scotia Capital on Friday, August 7. The stock of Canadian Natural Resources Limited (NYSE:CNQ) has “Top Pick” rating given on Friday, March 10 by RBC Capital Markets. RBC Capital Markets maintained it with “Outperform” rating and $39 target in Friday, November 6 report. Raymond James upgraded the shares of CNQ in report on Friday, August 7 to “” rating. Macquarie Research downgraded Canadian Natural Resources Limited (NYSE:CNQ) on Friday, January 8 to “Neutral” rating. Morgan Stanley maintained Canadian Natural Resources Limited (NYSE:CNQ) rating on Friday, October 13. Morgan Stanley has “Overweight” rating and $52 target. The stock of Canadian Natural Resources Limited (NYSE:CNQ) has “Outperform” rating given on Friday, December 16 by Wells Fargo. Goldman Sachs maintained Canadian Natural Resources Limited (NYSE:CNQ) on Thursday, June 22 with “Buy” rating.

Mackenzie Financial Corp increased Aercap Holdings Nv (NYSE:AER) stake by 51,056 shares to 151,056 valued at $7.72 million in 2017Q3. It also upped Textron Inc (NYSE:TXT) stake by 12,512 shares and now owns 115,939 shares. Delta Air Lines Inc Del (NYSE:DAL) was raised too.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>